Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria

Shares :

0
(0)

Toronto, Ontario–(Newsfile Corp. – December 23, 2020) –  Psyched Wellness Ltd.(formerly Duncan Park Holdings Corporation) (CSE: PSYC) (OTCQB: DCNPF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to share that it has shipped its first batch of Amanita Muscaria extract to its CRO partner to commence the Pre-Clinical trials. 

The Company sent 108 grams of highly concentrated Amanita Muscaria extract to its CRO’s lab to begin the first phase of its Pre-Clinical Trial. This first batch of Amanita extract will be used in a study to determine the Maximum Tolerated Dose (MTD). The goal of the study is to determine the highest dose of our extract that will not cause unacceptable side effects or an overt toxicity in a defined period. This is a key first step in determining the appropriate dosage for our future products. 

Jeff Stevens, CEO of the Company says, “This is a major milestone for Psyched Wellness! We have now officially commenced our Pre-Clinical Trials to determine the safety, efficacy, and safe dosage levels for Amanita Muscaria. This is a key step, as it is the foundation off which we can apply to the FDA for a New Dietary Ingredient (NDI) and Health Canada for a Natural Health Product Number (NHPN) for our Amanita Muscaria supplement. It will also provide the IP required to focus our team’s attention on studying other more clinical uses of Amanita Muscaria for mental and physical health issues.”

For further information, please contact: 

Jeffrey Stevens
Chief Executive Officer 
Psyched Wellness Ltd. 
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com
Website: http://www.psyched-wellness.com

Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :